4.4 Review

Current and emerging maintenance therapies for ulcerative colitis

期刊

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1586/17474124.2014.896193

关键词

thiopurines; adalimumab; maintenance; remission; infliximab; 5-ASA; golimumab; ulcerative colitis

资金

  1. MSD Human Health
  2. Pfizer
  3. Salix
  4. Shire
  5. Aptalis

向作者/读者索取更多资源

Ulcerative colitis (UC) is a chronic idiopathic intestinal disease that requires life-long maintenance therapy to maintain clinical remission. This article reviews the current literature on maintenance treatments in UC. It examines the natural history of the condition and the proposed benefits of treatment. These include improving quality of life parameters, decreasing corticosteroid intake, the prevention of relapse, the prevention of colorectal cancer and the avoidance of colectomy. The immunosuppressive era appears to be reducing the need for elective colectomy in UC. The article explores the classes of drug currently used for maintenance of UC, reviews the literature around adherence issues, and summarizes emerging agents in this space.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据